双向量rAAVrh8基因疗法用于GM2性化症:一期1/2试验
Florian Eichler1,2, Oguz I Cataltepe3, Rrita Daci3,4
1Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Nature medicine
|August 15, 2025
概括
使用双重AAV载体的基因治疗成功恢复了Tay-Sachs和Sandhoff疾病的儿童的酶活性并改善了结果. 这种方法显示了剂量依赖的校正,稳定了婴儿患者,并减少了发作的严重程度.
科学领域:
- 神经学 神经学
- 遗传学 遗传学 是一个
- 生物技术是生物技术.
背景情况:
- 包括Tay-Sachs和Sandhoff疾病在内的GM2性化症是由于素胺酶 (Hex) 缺乏导致的.
- 目前的治疗方法有限,需要新的治疗策略,如基因治疗.
研究的目的:
- 评估婴幼儿和青少年Tay-Sachs和Sandhoff疾病的儿童双重腺相关病毒 (AAV) 基因疗法的安全性和有效性.
- 为了评估基因治疗后的剂量依赖的生化和临床反应.
主要方法:
- 阶段1/2,剂量升级研究,涉及对rAAVrh8-HEXA和rAAVrh8-HEXB载体的同时双体 (BiT),体内和体内给药.
- 四组儿童 (六名婴儿,三名青少年) 接受了基因疗法的升级剂量.
- 治疗后对生化标志物 (Hex酶活性,GM2水平) 和临床结果进行了监测.
主要成果:
- 基因疗法证明了对Hex酶活性的剂量依赖性纠正以及脑脊液和血清中GM2水平的降低.
- 婴儿患者显示全球临床稳定,长时间口服养,并延迟/减轻严重发作.
- 神经成像显示纤维通道增加;生化纠正在12周达到峰值,并在24周下降.
结论:
- 双重AAV基因疗法是治疗Tay-Sachs和Sandhoff疾病的有希望的方法,提供了显著的生物化学和临床益处.
- 虽然在婴儿患者中有效,但青少年患者经历了像 dystonia 这样的不良事件,表明潜在的与年龄相关的反应差异.
- 进一步的研究是有必要的,以优化剂量和了解长期的疗效和安全性.
相关概念视频
00:59Gene Therapy
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
00:59Gene Therapy
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
01:03Rous Sarcoma Virus (RSV) and Cancer
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
01:03Rous Sarcoma Virus (RSV) and Cancer
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...